These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8830021)

  • 21. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
    Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
    Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S; Kamiyama T; Fukuda Y; Takahata M; Mitsuyama J
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.
    Bogdanovich T; Esel D; Kelly LM; Bozdogan B; Credito K; Lin G; Smith K; Ednie LM; Hoellman DB; Appelbaum PC
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3325-33. PubMed ID: 16048943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-vitro and in-vivo antibacterial activity of CFC-222, a new fluoroquinolone.
    Kim JH; Choi KH; Kim JW; Lee JH; Choi EC; Kim BK
    J Antimicrob Chemother; 1998 Feb; 41(2):223-9. PubMed ID: 9533464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro activity of four new fluoroquinolones.
    García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
    J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
    Linde HJ; Schmidt M; Fuchs E; Reischl U; Niller HH; Lehn N
    Antimicrob Agents Chemother; 2001 May; 45(5):1553-7. PubMed ID: 11302827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents.
    Ford AS; Baltch AL; Smith RP; Ritz W
    J Antimicrob Chemother; 1993 Apr; 31(4):523-32. PubMed ID: 8390434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-staphylococcal activity of temafloxacin, ciprofloxacin, ofloxacin and enoxacin.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1991 Nov; 28(5):695-9. PubMed ID: 1663929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Study on the activities of fluoroquinolones against Staphylococcus aureus and the effect of reserpine on these activities].
    Zhong L; Feng P; Fan X; Lü X; Yu R; Liao F; Lei B
    Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):91-3. PubMed ID: 12599439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The bactericidal activity of sparfloxacin.
    Lewin CS; Morrissey I; Smith JT
    J Antimicrob Chemother; 1992 Nov; 30(5):625-32. PubMed ID: 1337350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology.
    Visalli MA; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 1996 Jan; 37(1):77-84. PubMed ID: 8647777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of trovafloxacin versus ceftriaxone in the treatment of experimental brain abscess/cerebritis in the rat.
    Nathan BR; Scheld WM
    Life Sci; 2003 Aug; 73(14):1773-82. PubMed ID: 12888116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
    Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.
    Bédos JP; Azoulay-Dupuis E; Moine P; Muffat-Joly M; Veber B; Pocidalo JJ; Vallée E
    J Pharmacol Exp Ther; 1998 Jul; 286(1):29-35. PubMed ID: 9655838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.